Curcumin attenuates prostatic hyperplasia caused by inflammation via up-regulation of bone morphogenetic protein and activin membrane-bound inhibitor

References

• Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van KP, Victor A, Wein A, Standardisation Sub-committee of the International Continence Society. 2002. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Akanni OO, Owumi SE, Olowofela OG, Adeyanju AA, Abiola OJ, Adaramoye OA. 2020. Protocatechuic acid ameliorates testosterone-induced benign prostatic hyperplasia through the regulation of inflammation and oxidative stress in castrated rats. J Biochem Mol Toxicol. 34(8):e22502.
   PubMed Web of Science ®Google Scholar
• Apte RN, Voronov E. 2002. Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol. 12(4):277–290.
   PubMed Web of Science ®Google Scholar
• Atabaki R, Roohbakhsh A, Moghimi A, Mehri S. 2020. Protective effects of maternal administration of curcumin and hesperidin in the rat offspring following repeated febrile seizure: Role of inflammation and TLR4. Int Immunopharmacol. 86:106720.
   PubMed Web of Science ®Google Scholar
• Bahrami A, Majeed M, Sahebkar A. 2019. Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition. Cell Oncol. 42(4):405–421.
   Web of Science ®Google Scholar
• Bechis SK, Otsetov AG, Ge R, Olumi AF. 2014. Personalized medicine for the management of benign prostatic hyperplasia. J Urol. 192(1):16–23.
   PubMed Web of Science ®Google Scholar
• Chughtai B, Forde JC, Thomas DDM, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. 2016. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2:16031.
   PubMed Web of Science ®Google Scholar
• Cosentino V, Fratter A, Cosentino M. 2016. Anti-inflammatory effects exerted by Killox®, an innovative formulation of food supplement with curcumin, in urology. Eur Rev Med Pharmacol Sci. 20(7):1390–1398.
   PubMed Web of Science ®Google Scholar
• Das L, Vinayak M. 2014. Long-term effect of curcumin down-regulates expression of tumor necrosis factor-α and interleukin-6 via modulation of E26 transformation-specific protein and nuclear factor-κB transcription factors in livers of lymphoma bearing mice. Leuk Lymphoma. 55(11):2627–2636.
   PubMed Web of Science ®Google Scholar
• De NC, Presicce F, Tubaro A. 2016. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 13(10):613–626.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Simental-Mendía LE, Bo S, Sahebkar A. 2016. Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 111:394–404.
   PubMed Web of Science ®Google Scholar
• Du YF, Long QZ, Zhang L, Shi Y, Liu XG, Li XD, Guan B, Tian YC, Wang XY, Li L, et al. 2015. Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling. Int J Oncol. 47(6):2064–2072.
   PubMed Web of Science ®Google Scholar
• Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F. 2013. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 112(4):432–441.
   PubMed Web of Science ®Google Scholar
• Geusens P, Emans PJ, De JJJA, Van DBJ. 2013. NSAIDs and fracture healing. Curr Opin Rheumatol. 25(4):524–531.
   PubMed Web of Science ®Google Scholar
• Gu JS, Sun RR, Shen S, Yu ZJ. 2015. The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer. Onco Targets Ther. 8:2215–2225.
   PubMed Web of Science ®Google Scholar
• Gupta K, Yezdani M, Sotelo T, Aragon-Ching JB. 2015. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 24(8):1059–1073.
   PubMed Web of Science ®Google Scholar
• He Y, Ou ZY, Chen X, Zu XB, Liu LF, Li Y, Cao ZZ, Chen MF, Chen Z, Chen HQ, et al. 2016. LPS/TLR4 signaling enhances TGF-β response through downregulating BAMBI during prostatic hyperplasia. Sci Rep. 6(1):27051–27013.
   PubMedGoogle Scholar
• Hu S, Yu W, Lv TJ, Chang CS, Li X, Jin J. 2014. Evidence of TGF-β1 mediated epithelial-mesenchymal transition in immortalized benign prostatic hyperplasia cells. Mol Membr Biol. 31(2–3):103–110.
   PubMed Web of Science ®Google Scholar
• Jain SK, Rains J, Croad J, Larson B, Jones K. 2009. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal. 11(2):241–249.
   PubMed Web of Science ®Google Scholar
• Karimian MS, Pirro M, Majeed M, Sahebkar A. 2017. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. 33:55–63.
   PubMed Web of Science ®Google Scholar
• Kim SK, Seok H, Park HJ, Jeon HS, Kang SW, Lee BC, Yi J, Song SY, Lee SH, Kim Young O, Chung JH. 2015. Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complement Altern Med. 15:380–386.
   PubMed Web of Science ®Google Scholar
• Kong DS, Zhang F, Shao JJ, Wu L, Zhang XP, Chen L, Lu Y, Zheng SZ. 2015. Curcumin inhibits cobalt chloride-induced epithelial-to-mesenchymal transition associated with interference with TGF-β/Smad signaling in hepatocytes. Lab Invest. 95(11):1234–1245.
   PubMed Web of Science ®Google Scholar
• Kumari A, Dash D, Singh R. 2017. Curcumin inhibits lipopolysaccharide (LPS)-induced endotoxemia and airway inflammation through modulation of sequential release of inflammatory mediators (TNF-α and TGF-β1) in murine model. Inflammopharmacology. 25(3):329–341.
   PubMed Web of Science ®Google Scholar
• Lu TJ, Lin WJ, Izumi K, Wang XH, Xu DF, Fang LY, Li L, Jiang Q, Jin J, Chang CS. 2012. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol Endocrinol. 26(10):1707–1715.
   PubMedGoogle Scholar
• Madersbacher S, Sampson N, Culig Z. 2019. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 65(5):458–464.
   PubMed Web of Science ®Google Scholar
• Ma J, Ma SY, Ding CH. 2017. Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor β1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinase 1. Chin J Integr Med. 23(5):362–369.
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE, Gonzalez CM, Kaplan SA, Penson DF, et al. 2011. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 185(5):1793–1803.
   PubMed Web of Science ®Google Scholar
• Nguyen DP, Li JY, Tewari AK. 2014. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 113(6):986–992.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. 2016. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol. 196(5):1493–1498.
   PubMed Web of Science ®Google Scholar
• Nonn L, Duong D, Peehl DM. 2007. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 28(6):1188–1196.
   PubMed Web of Science ®Google Scholar
• Patel SS, Acharya A, Ray RS, Agrawal R, Raghuwanshi R, Jain P. 2020. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr. 60(6):887–939.
   PubMed Web of Science ®Google Scholar
• Rho J, Seo CS, Park HS, Jeong HY, Moon OS, Seo YW, Son HY, Won YS, Kwun HJ. 2020. Asteris radix et rhizoma suppresses testosterone-induced benign prostatic hyperplasia in rats by regulating apoptosis and inflammation. J Ethnopharmacol. 255:112779.
   PubMed Web of Science ®Google Scholar
• Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, Taille A. 2009. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 69(16):1774–1780.
   PubMed Web of Science ®Google Scholar
• Shao R, Shi JD, Liu HT, Shi XY, Du XL, Klocker H, Lee C, Zhu Y, Zhang J. 2014. Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia. Prostate. 74(9):970–982.
   PubMed Web of Science ®Google Scholar
• Speakman M, Kirby R, Doyle S, Ioannou C. 2015. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) – focus on the UK. BJU Int. 115(4):508–519.
   PubMed Web of Science ®Google Scholar
• Ventura S, Oliver VI, White CW, Xie JH, Haynes JM, Exintaris B. 2011. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 163(5):891–907.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. 2014. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 37(4):313–322.
   PubMed Web of Science ®Google Scholar
• Wang ZH, Chen Z, Li BS, Zhang B, Du YC, Liu YH, He Y, Chen X. 2020. Curcumin attenuates renal interstitial fibrosis of obstructive nephropathy by suppressing epithelial-mesenchymal transition through inhibition of the TLR4/NF-кB and PI3K/AKT signaling pathways. Pharm Biol. 58(1):828–837.
   PubMed Web of Science ®Google Scholar
• Xu DQ, Chen P, Xiao H, Wang XH, DiSanto ME, Zhang XH. 2019. Upregulated interleukin 21 receptor enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia. Front Endocrinol. 10:4–11.
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu PH, Zhou Y, Chen Z, He Y, Mo M, Dai GY, Xia WP, Du YC, Liu YH, et al. 2019. Dihydroartemisinin attenuates renal fibrosis through regulation of fibroblast proliferation and differentiation. Life Sci. 223:29–37.
   PubMed Web of Science ®Google Scholar
• Zhou J, Lei YF, Chen JL, Zhou XL. 2018. Potential ameliorative effects of epigallocatechin‑3‑gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats. Int Immunopharmacol. 64:162–169.
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, Takahashi H, Kuk C, Kovylina M, Aldaoud N, et al. 2014. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol. 66(4):619–622.
   PubMed Web of Science ®Google Scholar